Cancer Research Meeting Calendar Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Herwaarden, A. E.
Right arrow Articles by Schinkel, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Herwaarden, A. E.
Right arrow Articles by Schinkel, A. H.
[Cancer Research 63, 6447-6452, October 1, 2003]
© 2003 American Association for Cancer Research

Regular Articles

The Breast Cancer Resistance Protein (Bcrp1/Abcg2) Restricts Exposure to the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine1

Antonius E. van Herwaarden, Johan W. Jonker, Els Wagenaar, Remco F. Brinkhuis, Jan H. M. Schellens, Jos H. Beijnen and Alfred H. Schinkel2

Division of Experimental Therapy [A. E. v. H., J. W. J., E. W., R. F. B., A. H. S.] and Divisions of Experimental Therapy and Medical Oncology [J. H. M. S.], The Netherlands Cancer Institute, 1066 CX Amsterdam, and Department of Pharmacy and Pharmacology, Slotervaart Hospital, 1066 EC Amsterdam [J. H. B.], The Netherlands

The food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is the most abundant heterocyclic amine found in various protein containing foods. PhIP is mutagenic and carcinogenic in rodents, inducing lymphomas in mice and colon, mammary and prostate carcinomas in rats. It has also been implicated in human breast carcinogenesis. Humans on a normal Western diet are exposed to PhIP on a daily basis. The breast cancer resistance protein (BCRP/ABCG2) transports various anticancer drugs from cells, causing multidrug resistance. By its presence in the apical membrane of the intestine and bile canalicular membrane, it also protects the body from substrate drugs and toxins. We investigated whether Bcrp1 could affect PhIP exposure of the body because this could implicate BCRP activity in the cancer risk due to PhIP. Using polarized cell lines, we found that PhIP is efficiently transported by murine Bcrp1. In vivo pharmacokinetic studies showed that at a dose of 1 mg/kg [14C]PhIP the area under the curve for oral administration was 2.9-fold higher in Bcrp1-/- compared with wild-type mice (306 ± 39 versus 107 ± 15 h·ng/ml) and, for i.v. administration, 2.2 fold higher (386 ± 36 versus 178 ± 8.9 h·ng/ml). Wild-type mice cleared [14C]PhIP mainly by fecal excretion, but this shifted to primarily urinary excretion in Bcrp1-/- mice. In mice with a cannulated gall bladder, both hepatobiliary and direct intestinal excretion of [14C]PhIP were greatly impaired in Bcrp1-/- compared with wild-type mice (9.0 ± 4.4 versus 36.5 ± 9.4% and 1.5 ± 0.8 versus 4.2 ± 1.5%, respectively). We conclude that Bcrp1 effectively restricts the exposure of mice to ingested PhIP by decreasing its uptake from the gut lumen and by mediating hepatobiliary and intestinal elimination. Intra- or interindividual differences in BCRP activity in humans may thus also affect the exposure to PhIP and related food carcinogens, with possible implications for cancer susceptibility.




This article has been cited by other articles:


Home page
 Sci Transl MedHome page
H. Matsuo, T. Takada, K. Ichida, T. Nakamura, A. Nakayama, Y. Ikebuchi, K. Ito, Y. Kusanagi, T. Chiba, S. Tadokoro, et al.
Common Defects of ABCG2, a High-Capacity Urate Exporter, Cause Gout: A Function-Based Genetic Analysis in a Japanese Population
Science Translational Medicine, November 4, 2009; 1(5): 5ra11 - 5ra11.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
R. van de Ven, R. Oerlemans, J. W. van der Heijden, G. L. Scheffer, T. D. de Gruijl, G. Jansen, and R. J. Scheper
ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer
J. Leukoc. Biol., November 1, 2009; 86(5): 1075 - 1087.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Arias, S. S. M. Villanueva, M. L. Ruiz, M. G. Luquita, L. M. Veggi, J. M. Pellegrino, M. Vore, V. A. Catania, and A. D. Mottino
Regulation of Expression and Activity of Rat Intestinal Multidrug Resistance-Associated Protein 2 by Cholestatic Estrogens
Drug Metab. Dispos., June 1, 2009; 37(6): 1277 - 1285.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
L. Zhou, K. Schmidt, F. R. Nelson, V. Zelesky, M. D. Troutman, and B. Feng
The Effect of Breast Cancer Resistance Protein and P-Glycoprotein on the Brain Penetration of Flavopiridol, Imatinib Mesylate (Gleevec), Prazosin, and 2-Methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic Acid (PF-407288) in Mice
Drug Metab. Dispos., May 1, 2009; 37(5): 946 - 955.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L.H. Vlaming, Z. Pala, A. van Esch, E. Wagenaar, D. R. de Waart, K. van de Wetering, C. M.M. van der Kruijssen, R. P.J. Oude Elferink, O. van Tellingen, and A. H. Schinkel
Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo
Clin. Cancer Res., May 1, 2009; 15(9): 3084 - 3093.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L.H. Vlaming, Z. Pala, A. van Esch, E. Wagenaar, O. van Tellingen, D. R. de Waart, R. P.J. Oude Elferink, K. van de Wetering, and A. H. Schinkel
Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the In vivo Elimination of Methotrexate and its Main Toxic Metabolite 7-hydroxymethotrexate
Clin. Cancer Res., December 15, 2008; 14(24): 8152 - 8160.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Kitamura, K. Maeda, Y. Wang, and Y. Sugiyama
Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin
Drug Metab. Dispos., October 1, 2008; 36(10): 2014 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Giri, N. Shaik, G. Pan, T. Terasaki, C. Mukai, S. Kitagaki, N. Miyakoshi, and W. F. Elmquist
Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse
Drug Metab. Dispos., August 1, 2008; 36(8): 1476 - 1484.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Marchetti, N. A. de Vries, T. Buckle, M. J. Bolijn, M. A.J. van Eijndhoven, J. H. Beijnen, R. Mazzanti, O. van Tellingen, and J. H.M. Schellens
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice
Mol. Cancer Ther., August 1, 2008; 7(8): 2280 - 2287.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Enokizono, H. Kusuhara, A. Ose, A. H. Schinkel, and Y. Sugiyama
Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds
Drug Metab. Dispos., June 1, 2008; 36(6): 995 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
X. Liu, C. Chen, and B. J. Smith
Progress in Brain Penetration Evaluation in Drug Discovery and Development
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Matsushima, K. Maeda, H. Hayashi, Y. Debori, A. H. Schinkel, J. D. Schuetz, H. Kusuhara, and Y. Sugiyama
Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine
Mol. Pharmacol., May 1, 2008; 73(5): 1474 - 1483.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Vore and M. Leggas
Progesterone Acts via Progesterone Receptors A and B to Regulate Breast Cancer Resistance Protein Expression
Mol. Pharmacol., March 1, 2008; 73(3): 613 - 615.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Kobayashi, K. Saito, T. Moritomo, K. Araki, F. Takizawa, and T. Nakanishi
Characterization and localization of side population (SP) cells in zebrafish kidney hematopoietic tissue
Blood, February 1, 2008; 111(3): 1131 - 1137.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. K.W. To, O. Polgar, L. M. Huff, K. Morisaki, and S. E. Bates
Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells
Mol. Cancer Res., January 1, 2008; 6(1): 151 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. Enokizono, H. Kusuhara, and Y. Sugiyama
Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens
Mol. Pharmacol., October 1, 2007; 72(4): 967 - 975.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
L.-L. Hu, X.-X. Wang, X. Chen, J. Chang, C. Li, Y. Zhang, J. Yang, W. Jiang, and S.-M. Zhuang
BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma
Carcinogenesis, August 1, 2007; 28(8): 1740 - 1744.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Yamagata, H. Kusuhara, M. Morishita, K. Takayama, H. Benameur, and Y. Sugiyama
Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients
Drug Metab. Dispos., July 1, 2007; 35(7): 1142 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
J. W. Jonker, S. Musters, M. L. H. Vlaming, T. Plosch, K. E. R. Gooijert, M. J. Hillebrand, H. Rosing, J. H. Beijnen, H. J. Verkade, and A. H. Schinkel
Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX
Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2204 - C2212.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. E. van Herwaarden, E. Wagenaar, G. Merino, J. W. Jonker, H. Rosing, J. H. Beijnen, and A. H. Schinkel
Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk
Mol. Cell. Biol., February 15, 2007; 27(4): 1247 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
X. Wang and M. E. Morris
Effects of the Flavonoid Chrysin on Nitrofurantoin Pharmacokinetics in Rats: Potential Involvement of ABCG2
Drug Metab. Dispos., February 1, 2007; 35(2): 268 - 274.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. Enokizono, H. Kusuhara, and Y. Sugiyama
Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the Biliary Excretion and Intestinal Efflux of Troglitazone Sulfate, the Major Metabolite of Troglitazone with a Cholestatic Effect
Drug Metab. Dispos., February 1, 2007; 35(2): 209 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
K. K. W. To, Z. Zhan, and S. E. Bates
Aberrant Promoter Methylation of the ABCG2 Gene in Renal Carcinoma
Mol. Cell. Biol., November 15, 2006; 26(22): 8572 - 8585.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi
Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System.
Physiol Rev, October 1, 2006; 86(4): 1179 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. L. H. Vlaming, K. Mohrmann, E. Wagenaar, D. R. de Waart, R. P. J. O. Elferink, J. S. Lagas, O. van Tellingen, L. D. Vainchtein, H. Rosing, J. H. Beijnen, et al.
Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 319 - 327.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, et al.
A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1114 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. Wang, L. Zhou, A. Gupta, R. R. Vethanayagam, Y. Zhang, J. D. Unadkat, and Q. Mao
Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells
Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E798 - E807.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K.-i. Nezasa, X. Tian, M. J. Zamek-Gliszczynski, N. J. Patel, T. J. Raub, and K. L. R. Brouwer
ALTERED HEPATOBILIARY DISPOSITION OF 5 (AND 6)-CARBOXY-2',7'-DICHLOROFLUORESCEIN IN Abcg2 (Bcrp1) AND Abcc2 (Mrp2) KNOCKOUT MICE
Drug Metab. Dispos., April 1, 2006; 34(4): 718 - 723.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
G. Merino, A. I. Alvarez, M. M. Pulido, A. J. Molina, A. H. Schinkel, and J. G. Prieto
BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) TRANSPORTS FLUOROQUINOLONE ANTIBIOTICS AND AFFECTS THEIR ORAL AVAILABILITY, PHARMACOKINETICS, AND MILK SECRETION
Drug Metab. Dispos., April 1, 2006; 34(4): 690 - 695.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. E.v. Herwaarden, E. Wagenaar, B. Karnekamp, G. Merino, J. W. Jonker, and A. H. Schinkel
Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk
Carcinogenesis, January 1, 2006; 27(1): 123 - 130.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
B. Ebert, A. Seidel, and A. Lampen
Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists
Carcinogenesis, October 1, 2005; 26(10): 1754 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Hirano, K. Maeda, S. Matsushima, Y. Nozaki, H. Kusuhara, and Y. Sugiyama
Involvement of BCRP (ABCG2) in the Biliary Excretion of Pitavastatin
Mol. Pharmacol., September 1, 2005; 68(3): 800 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Tahara, H. Kusuhara, E. Fuse, and Y. Sugiyama
P-GLYCOPROTEIN PLAYS A MAJOR ROLE IN THE EFFLUX OF FEXOFENADINE IN THE SMALL INTESTINE AND BLOOD-BRAIN BARRIER, BUT ONLY A LIMITED ROLE IN ITS BILIARY EXCRETION
Drug Metab. Dispos., July 1, 2005; 33(7): 963 - 968.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Takada, H. Suzuki, Y. Gotoh, and Y. Sugiyama
REGULATION OF THE CELL SURFACE EXPRESSION OF HUMAN BCRP/ABCG2 BY THE PHOSPHORYLATION STATE OF AKT IN POLARIZED CELLS
Drug Metab. Dispos., July 1, 2005; 33(7): 905 - 909.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. R. Vethanayagam, H. Wang, A. Gupta, Y. Zhang, F. Lewis, J. D. Unadkat, and Q. Mao
FUNCTIONAL ANALYSIS OF THE HUMAN VARIANTS OF BREAST CANCER RESISTANCE PROTEIN: I206L, N590Y, AND D620N
Drug Metab. Dispos., June 1, 2005; 33(6): 697 - 705.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. L. A. Sesink, I. C. W. Arts, V. C. J. de Boer, P. Breedveld, J. H. M. Schellens, P. C. H. Hollman, and F. G. M. Russel
Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Net Intestinal Uptake of Quercetin in Rats by Facilitating Apical Efflux of Glucuronides
Mol. Pharmacol., June 1, 2005; 67(6): 1999 - 2006.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
G. Merino, J. W. Jonker, E. Wagenaar, M. M. Pulido, A. J. Molina, A. I. Alvarez, and A. H. Schinkel
TRANSPORT OF ANTHELMINTIC BENZIMIDAZOLE DRUGS BY BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2)
Drug Metab. Dispos., May 1, 2005; 33(5): 614 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Merino, J. W. Jonker, E. Wagenaar, A. E. van Herwaarden, and A. H. Schinkel
The Breast Cancer Resistance Protein (BCRP/ABCG2) Affects Pharmacokinetics, Hepatobiliary Excretion, and Milk Secretion of the Antibiotic Nitrofurantoin
Mol. Pharmacol., May 1, 2005; 67(5): 1758 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
G. Merino, A. E. van Herwaarden, E. Wagenaar, J. W. Jonker, and A. H. Schinkel
Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver
Mol. Pharmacol., May 1, 2005; 67(5): 1765 - 1771.
[Abstract] [Full Text] [PDF]

Home page
 aacrmtgHome page
A. H. Schinkel
Functions of the ABC transporter breast cancer resistance protein (BCRP/ABCG2)
AACR Meeting Abstracts, April 1, 2005; 2005(1): 1475 - 1476.
[Abstract]

Home page
 Mol. Pharmacol.Home page
Y. Adachi, H. Suzuki, A. H. Schinkel, and Y. Sugiyama
Role of Breast Cancer Resistance Protein (Bcrp1/Abcg2) in the Extrusion of Glucuronide and Sulfate Conjugates from Enterocytes to Intestinal Lumen
Mol. Pharmacol., March 1, 2005; 67(3): 923 - 928.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Imai, E. Ishikawa, S. Asada, and Y. Sugimoto
Estrogen-Mediated Post transcriptional Down-regulation of Breast Cancer Resistance Protein/ABCG2
Cancer Res., January 15, 2005; 65(2): 596 - 604.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Ueda, S. Brenner, H. L. Malech, S. M. Langemeijer, S. Perl, M. Kirby, O. A. Phang, A. E. Krouse, R. E. Donahue, E. M. Kang, et al.
Cloning and Functional Analysis of the Rhesus Macaque ABCG2 Gene: FORCED EXPRESSION CONFERS AN SP PHENOTYPE AMONG HEMATOPOIETIC STEM CELL PROGENY IN VIVO
J. Biol. Chem., January 14, 2005; 280(2): 991 - 998.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Y.-J. Lee, H. Kusuhara, J. W. Jonker, A. H. Schinkel, and Y. Sugiyama
Investigation of Efflux Transport of Dehydroepiandrosterone Sulfate and Mitoxantrone at the Mouse Blood-Brain Barrier: A Minor Role of Breast Cancer Resistance Protein
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 44 - 52.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Pavek, G. Merino, E. Wagenaar, E. Bolscher, M. Novotna, J. W. Jonker, and A. H. Schinkel
Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 144 - 152.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C G Dietrich, A Geier, H E Wasmuth, S Matern, C Gartung, D R de Waart, and R P J O Elferink
Influence of biliary cirrhosis on the detoxification and elimination of a food derived carcinogen
Gut, December 1, 2004; 53(12): 1850 - 1855.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
N. Mizuno, M. Suzuki, H. Kusuhara, H. Suzuki, K. Takeuchi, T. Niwa, J. W. Jonker, and Y. Sugiyama
IMPAIRED RENAL EXCRETION OF 6-HYDROXY-5,7-DIMETHYL-2-METHYLAMINO-4-(3-PYRIDYLMETHYL) BENZOTHIAZOLE (E3040) SULFATE IN BREAST CANCER RESISTANCE PROTEIN (BCRP1/ABCG2) KNOCKOUT MICE
Drug Metab. Dispos., September 1, 2004; 32(9): 898 - 901.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.